Novo Nordisk ends legal proceedings against Hims & Hers
Nordisk has dropped its legal case against telehealth provider him and her for patent infringement, after the two companies agreed…
iShares US Pharmaceuticals ETF
Eli Lilly Launches Program to Increase Employer Coverage of Obesity Drugs
Eli Lilly On Thursday it launched a new program designed to help more employers cover obesity medications in the U.S.,…
Why Novo Nordisk's expansion in Ireland is key to fighting Eli Lilly
Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capabilities to…
Novartis and Genentech sue for illegal importation of prescription drugs
A sign for Swiss pharmaceutical giant Novartis is seen atop a building in Basel, Switzerland, on September 9, 2025. Fabrice…
What's next for Novo Nordisk's anti-obesity drug CagriSema?
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
Eli Lilly launches anti-obesity drug Zepbound with one-month dosage
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York on March 28, 2024.…
Novo Nordisk Shares Fall as Weight Loss Drug Fails to Beat Eli Lilly
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, November 5, 2025. Nichlas Pollier | Bloomberg | fake images…